Why do tirzepatide and semaglutide side effects worsen at dose steps?
Side effects of tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) often flare after a dose increase because gut side effects rise with dose, and a new dose keeps building for about 4 weeks. US and EU labels say nausea, vomiting and diarrhoea are most common during dose steps and ease over time. A prescriber can delay the next step.
Why do side effects flare after a dose increase?
Gut side effects of both medicines rise with dose, and labels say they are most common while the dose is being stepped up.13
In the US Zepbound weight-loss trials, vomiting rose with dose. It affected 8% of people on 5 mg, 11% on 10 mg and 13% on 15 mg, against 2% on placebo. Diarrhoea rose from 19% to 23%, against 8%.1 Severe gut reactions rose too, from 1.7% on 5 mg to 3.1% on 15 mg, against 1% on placebo.1
The US Zepbound label says most nausea, vomiting and diarrhoea happened during dose steps and decreased over time. The EU Mounjaro product information says the same.13
For Wegovy injection, the US label reports nausea in 44% of people, against 16% on placebo, most often during dose steps.2 The EU Wegovy product information says gut reactions were mainly seen in the step-up period.4 A pooled analysis of the STEP trials calls gut side effects a dose-dependent effect of this drug class.5
Both medicines slow how fast the stomach empties.12 The US Zepbound label says this slowing is largest after the first dose and fades over time.1
Why can the later weeks of a new dose feel worse?
Each weekly dose adds to what is still in your body, so levels keep climbing for about 4 weeks after a step.14
The US Zepbound label gives tirzepatide a half-life of about 5 to 6 days. It says steady levels are reached after 4 weeks of weekly doses.1 The US Wegovy label gives semaglutide a half-life of about 1 week.2 The EU product information says daily Wegovy tablets reach steady levels after 4 to 5 weeks.4
In the pooled STEP 1 to 3 trials, semaglutide doses rose every 4 weeks until week 16. Nausea, diarrhoea and vomiting were most common around week 20, then fell, though they stayed above placebo.5 Single episodes were short, with median lengths of 8 days for nausea, 3 for diarrhoea and 2 for vomiting. Constipation lasted longer, a median of 47 days.5
Tiredness can rise too. Fatigue affected 5% to 7% of people on Zepbound, against 3% on placebo.1
What can a prescriber change if a new dose is too much?
Labels let a prescriber wait longer before the next step, and some allow a lower dose when a higher one is not tolerated.124
US and EU tirzepatide labels raise the dose in 2.5 mg steps, after at least 4 weeks on the current dose.13 The US Zepbound label suggests a lower maintenance dose if one is not tolerated.1
The US Wegovy label suggests delaying a step by 4 weeks if a dose is not tolerated. It allows 1.7 mg or 2.4 mg for weight maintenance.2 The EU Wegovy product information also allows going back to the previous dose until symptoms improve.4
Labels warn that vomiting and diarrhoea can cause dehydration and kidney injury. They advise checking kidney function in people with these symptoms, especially when starting or stepping up.12 Our answer on how much water to drink covers fluids.
A dose step can matter for contraception too. For people on a hormonal contraceptive pill, the US Zepbound label advises switching to a non-pill method or adding a barrier method. This applies for 4 weeks after starting and after each step up.1
What do people on GLP-1 medicines report after a dose increase?
From public patient forums: 70 Reddit threads in r/Zepbound, r/Mounjaro, r/WegovyWeightLoss, r/Ozempic, r/mounjarouk and r/WegovyPillWeightLoss, read across posts from October 2025 to October 2026. Personal reports, not medical evidence.
What people describe
- Matches the label Many say a dose step brought new or worse side effects, mostly gut symptoms, even when earlier doses were easy. US labels say gut side effects were most common during dose steps.12
- Matches the label Several say later shots of a new dose felt worse than the first, and replies put this down to the medicine building up. The US Zepbound label says levels reach a steady state after 4 weeks of weekly doses.1
- Matches the label Many describe tiredness or exhaustion with a step-up. The US Zepbound label lists fatigue in 5% to 7% of people, against 3% on placebo.1
- Matches the trial Many say symptoms eased with time on the same dose, but several never adjusted, with symptoms lasting months or returning at every step. In the STEP trials, gut symptoms peaked around week 20 and then fell, though they stayed above placebo.5
- Matches the label Several describe severe episodes, including being unable to keep fluids down or needing hospital care. US labels report severe gut reactions and warn that dehydration can lead to kidney injury.12
Advice people share
- Matches the label Many advise going back to the last dose they tolerated, or holding a dose longer, with their prescriber. US and EU Wegovy labels allow a delayed step, and the EU label also allows a return to the previous dose.24
- Matches the NHS Many suggest small, bland, lower-fat meals around injection day. A 2024 diet review for these medicines suggests small, frequent meals. The NHS says avoiding fatty or spicy food may help with diarrhoea and vomiting.76
- Matches the label Many stress drinking fluids on a schedule. The US Zepbound Medication Guide says drinking fluids helps lower the chance of dehydration.1
- Label says otherwise Many describe making their own in-between doses, splitting doses or changing the gap between doses. The US Zepbound label sets once-weekly doses that rise in 2.5 mg steps, and the US Wegovy label says to swallow tablets whole.12
In your country
Why side effects flare at a dose step is the same everywhere, but labels differ on how far a prescriber can step back and on contraception advice.
Australia
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.
Label: The Australian Wegovy Product Information says to consider delaying a step until symptoms improve. It allows 1.7 mg for maintenance if 2.4 mg is not tolerated, with a return to 2.4 mg if tolerated.8 The Australian Mounjaro Product Information gives the same 4-week contraception advice after each step as the US label.9
Emergency number: 000
Canada
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.
Label: The Canadian Wegovy Product Monograph suggests delaying a step by 4 weeks. If 2.4 mg is not tolerated, it allows 1.7 mg for at most 4 weeks, then a return to 2.4 mg.10 The Canadian Mounjaro Product Monograph gives the same 4-week contraception advice after each step as the US label.11
Emergency number: 911
France
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).
Label: The EU Wegovy product information allows a delayed step or a return to the previous dose until symptoms improve.4 The EU Mounjaro product information calls the drop in pill hormone levels not clinically relevant and gives no 4-week barrier advice.3
Emergency number: 15 or 112
Germany
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.
Label: The EU Wegovy product information allows a delayed step or a return to the previous dose until symptoms improve.4 The EU Mounjaro product information calls the drop in pill hormone levels not clinically relevant and gives no 4-week barrier advice.3
Emergency number: 112
India
Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).
Label: We could not open an Indian label, so this page relies on the US labels and EU product information cited above.
Emergency number: 112
Saudi Arabia
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.
Label: We could not open a Saudi label, so this page relies on the US labels and EU product information cited above.
Emergency number: 997 or 911
United Arab Emirates
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.
Label: We could not open a UAE label, so this page relies on the US labels and EU product information cited above.
Emergency number: 998 for an ambulance, or 999
United Kingdom
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.
Label: The UK Wegovy SmPC says to consider delaying a step or lowering to the previous dose until symptoms improve.12 The UK Mounjaro SmPC gives the same 4-week contraception advice after each step as the US label.13
Emergency number: 999
United States
Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).
Label: The answer above applies.
Emergency number: 911
If you have not called for emergency help, stop the medicine and call your prescriber right away if severe stomach pain will not go away, with or without nausea or vomiting.1 Contact your prescriber or a doctor right away if nausea, vomiting or diarrhoea does not go away, or if you have upper-stomach pain, fever, yellow skin or eyes, or clay-coloured stools.1 The NHS advises urgent help if you keep being sick and cannot keep fluids down, or vomit for more than 2 days.6
Read the full picture
Related questions
Sources
- US Zepbound (tirzepatide) prescribing information and Medication Guide, Eli Lilly. Checked November 2026. uspl.lilly.com
- US Wegovy (semaglutide) prescribing information, injection and tablets, Novo Nordisk. Checked November 2026. DailyMed
- EU Mounjaro (tirzepatide) product information, European Medicines Agency. Checked November 2026. ema.europa.eu
- EU Wegovy (semaglutide) product information, injection and tablets, European Medicines Agency. Checked November 2026. ema.europa.eu
- Wharton S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab 2022. doi:10.1111/dom.14551. PubMed Central
- NHS. Diarrhoea and vomiting. nhs.uk
- Gentinetta S, Sottotetti F, Manuelli M, Cena H. Dietary recommendations for the management of gastrointestinal symptoms in patients treated with GLP-1 receptor agonist. 2024. PubMed Central
- Australian Wegovy (semaglutide) Product Information, Novo Nordisk. Checked November 2026. medsinfo.com.au
- Australian Mounjaro (tirzepatide) Product Information, Eli Lilly, version October 2026. medsinfo.com.au
- Canadian Wegovy (semaglutide injection) Product Monograph, Novo Nordisk Canada, Health Canada Drug Product Database. Checked November 2026. pdf.hres.ca
- Canadian Mounjaro (tirzepatide) Product Monograph, Eli Lilly Canada. Checked November 2026. pi.lilly.com
- UK Wegovy FlexTouch (semaglutide) Summary of Product Characteristics, emc. Checked November 2026. emc
- UK Mounjaro KwikPen (tirzepatide) Summary of Product Characteristics, emc. Checked November 2026. emc
- MedlinePlus. Recognizing medical emergencies (warning signs from the American College of Emergency Physicians). Reviewed January 2025. medlineplus.gov
Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked between Nov 9 and Nov 16, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write